Clinical Trial Update: A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection [Phase 2]

View source ↗

Summary

Phase 2 trial assessing Disitamab Vedotin combined with a PD-1 inhibitor and radiotherapy as a bladder-preserving treatment for localized HER2-high expressing m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• PD-1 inhibitor

Snippet

Sponsor: RenJi Hospital | Conditions: Bladder (Urothelial, Transitional Cell) Cancer | Phase 2 | Status: NOT_YET_RECRUITING